









Markets
/
Stocks
/
nasdaq-syre
/

Spyre Therapeutics Inc

SYRE

23.350USD

+1.170+5.28%

Close 11/11, 16:00（ET）Quotes delayed by 15 min

1.41BMarket Cap

LossP/E TTM



Spyre Therapeutics Inc

23.350

+1.170+5.28%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Spyre Therapeutics Inc

Currency: USD Updated: 2025-11-11

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a good stock market performance and strong technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Spyre Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

107 / 407

Overall Ranking

223 / 4608

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 13 analysts

Strong Buy

Current Rating

52.636

Target Price

+137.31%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Spyre Therapeutics Inc Highlights

StrengthsRisks

Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -9.22, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 65.04M shares, decreasing 10.59% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 15.50K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-11

The company's current financial score is 5.19, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.19

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.44

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.71

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Spyre Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-11

The company’s current valuation score is 5.85, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -9.22, which is -131.70% below the recent high of 2.92 and 0.00% above the recent low of -9.22.

Score

Industry at a Glance

Previous score

5.85

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 107/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-11

The company’s current earnings forecast score is 9.08, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Spyre Therapeutics Inc is 49.00, with a high of 70.00 and a low of 21.00.

Score

Industry at a Glance

Previous score

9.08

Change

Support & Resistance

No Data

Analyst Rating

Based on 13 analysts

Strong Buy

Current Rating

52.636

Target Price

+137.31%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Spyre Therapeutics Inc

SYRE

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-11

The company’s current price momentum score is 7.36, which is higher than the Biotechnology & Medical Research industry's average of 6.78. Sideways: Currently, the stock price is trading between the resistance level at 25.27 and the support level at 21.22, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.49

Change

-0.13

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.695

Neutral

RSI(14)

59.290

Neutral

STOCH(KDJ)(9,3,3)

45.749

Buy

ATR(14)

1.283

High Vlolatility

CCI(14)

-37.456

Neutral

Williams %R

43.606

Buy

TRIX(12,20)

0.896

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

22.658

Buy

MA10

23.260

Buy

MA20

23.170

Buy

MA50

19.254

Buy

MA100

17.779

Buy

MA200

17.474

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-11

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.13. The latest institutional shareholding proportion is 85.30%, representing a quarter-over-quarter decrease of 28.80%. The largest institutional shareholder is The Vanguard, holding a total of 3.04M shares, representing 3.92% of shares outstanding, with 16.81% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

8.61M

+4.54%

Fairmount Funds Management LLC

4.02M

RTW Investments L.P.

3.62M

BlackRock Institutional Trust Company, N.A.

3.58M

+11.50%

Deutsch (Peter E)

3.55M

+825.37%

Tang Capital Management, LLC

3.20M

The Vanguard Group, Inc.

Star Investors

3.06M

+5.82%

VR Adviser, LLC

2.69M

Braidwell LP

2.58M

Capital International Investors

2.39M

Risk Assessment

Currency: USD Updated: 2025-11-11

The company’s current risk assessment score is 4.66, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 3.17. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.